1.	A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M12-175, NCT01328626
2.	A Study of GDC-0199 (ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Patients With Chronic Lymphocytic Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GO28440, 2012-002351-42, NCT01671904
3.	A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: M13-365, NCT01682616
4.	A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GP28331, 2012-002038-34, NCT01685892